Zoladex leaves the PBS in November. AstraZeneca says it will stay free.

What just happened

Zoladex — the monthly goserelin 3.6mg implant used by more than 92,000 Australians in the past year for conditions including breast cancer, endometriosis, uterine fibroids, and precocious puberty — will be removed from the Pharmaceutical Benefits Scheme in November 2026.

AstraZeneca attributed the decision to PBS pricing constraints, stating the price offered was “too low, making it unsustainable to supply the medicine on the PBS.” For the patients and GPs managing their care, the immediate question was not why — it was how. How would those 92,000 annual dispensings continue, and at what cost?

This week, that question received a partial answer. AstraZeneca confirmed it will provide Zoladex at no cost from November for patients without a suitable alternative treatment. The program covers all current treatment indications and has no fixed end date. The announcement follows advocacy from the Breast Cancer Network Australia, patient groups, and professional bodies across oncology and women’s health.

---

The both-and

What the no-cost program means — and what it doesn’t

The commitment is meaningful. Goserelin is not a medication patients can easily substitute without clinical guidance, particularly for active hormone receptor-positive breast cancer treatment in pre- or peri-menopausal women, or for endometriosis managed after surgical intervention. Access continuing at no cost removes the most immediate concern.

Associate Professor Magdalena Simonis, a Melbourne GP specialising in women’s health, described the outcome as evidence of the power of collective advocacy. That framing is accurate. It also underlines the problem. The PBS’s purpose is precisely to remove the need for patient groups to lobby pharmaceutical companies for compassionate access. That the workaround succeeded does not mean the system functioned as intended.

What is not yet established is the practical access pathway. As of now, the process by which a GP prescribes, a pharmacy dispenses, or AstraZeneca delivers goserelin after November has not been detailed publicly. This gap — confirmed access at the policy level, uncertain access at the clinic counter — is the operational reality to watch. GPs should not assume the process will mirror a standard PBS script, because it will not.

The PBS under pressure — the bigger picture

The Australian Doctor coverage situates the goserelin decision within a broader pattern. Medicines Australia — the industry body for prescription medicine manufacturers — has reported that only 25% of medicines launched globally in the past decade have been listed on the Australian PBS, compared to 46% in the UK and 88% in the US. The Federal Health and Ageing Minister has described the medications market as being “in a state of enormous flux.”

Australia’s PBS pricing model, while protecting patients from catastrophic drug costs at the point of prescription, is increasingly pricing certain medications out of the scheme. What emerges in its place — patient access programs, manufacturer compassionate supply agreements, second-line substitutions — is not standardised, not audited, and not always available in time.

For GPs managing patients with established treatment regimens, this creates uncertainty that serves no clinical purpose. A patient stable on Zoladex for a specific oncological or gynaecological indication does not need a medication review driven by a PBS administrative decision. Yet that is effectively what November will require.

Who this affects in general practice

The RACGP coverage notes that while oncologists typically initiate goserelin prescriptions for breast cancer, GPs also manage patients receiving this treatment — administering the monthly subcutaneous injection, monitoring side effects including hot flushes, bone density changes, and mood effects, and providing continuity between specialist appointments.

For endometriosis, GPs often hold the long-term treatment relationship. The Breast Cancer Network Australia and women’s health organisations played a direct role in securing the no-cost commitment — a reminder that collective patient advocacy continues to shape pharmaceutical access policy in Australia in ways the regulatory process alone does not.

---

My two cents

The no-cost program announcement is genuinely good news for patients currently on Zoladex. However, “we will provide it at no cost” and “here is exactly how your GP prescribes it after 31 October” are different statements, and only one has been made.

For GPs managing patients on goserelin — whether for breast cancer, endometriosis, fibroids, or precocious puberty — the actionable steps right now are:

• Know which patients are on Zoladex and how long they have been on it
• Have a clinical conversation about the November transition while there is no urgency
• Watch for updated access pathway guidance from AstraZeneca and professional colleges — this will define what a “prescription” for Zoladex looks like from November 2026
• For patients on Zoladex for endometriosis where the PBS-listed leuprorelin might be a suitable alternative, discuss that option proactively rather than reactively

The broader PBS pattern — a medication exits, a patient access program fills the gap, the operational details arrive late — will not improve without structural reform. But the individual patients on Zoladex need individual plans well before that reform arrives.

Verdict: yes — worth knowing about.

---

Sources cited

1. Zoladex access ‘at no cost’ confirmed despite PBS removal. RACGP NewsGP, 20 July 2026. https://www1.racgp.org.au/newsgp/professional/zoladex-access-at-no-cost-confirmed-despite-pbs-re
2. AstraZeneca to provide goserelin implant direct to patients after PBS funding blow-up. Australian Doctor, 21 July 2026. https://www.ausdoc.com.au/news/astrazeneca-to-provide-goserelin-implant-direct-to-patients-after-pbs-funding-blow-up/
3. Breast Cancer Network Australia. https://www.bcna.org.au